Zelluna筹集了5 800万挪威克朗,将癌症治疗推向第一阶段试验。 Zelluna raised NOK 58 million to advance its cancer therapy into Phase I trials.

Zelluna ASA于2025年11月3日完成了一项私人安置和零售活动,筹集了5 800万挪威克朗,将ZI-MA4-1 TCR-NK疗法推进到第一阶段试验阶段。 Zelluna ASA completed a private placement and retail offering on November 3, 2025, raising NOK 58 million to advance its ZI-MA4-1 TCR-NK therapy into Phase I trials. 该公司在私人安置中发行了550万份股份,315 639份股份通过BiiritBid发行,股份贷款用于结算。 The company issued 5.5 million shares in the private placement and 315,639 via PrimaryBid, with share lending used for settlement. 在等待批准和市场条件之前,计划今后可能向现有股东提供多达80万股的股份。 A potential subsequent offering of up to 800,000 shares for existing shareholders is planned, pending approvals and market conditions. 发行的新份额总额可能达到661 500万,目的是加强资本和支持发展其现成的癌症治疗。 The total new shares issued could reach 6.615 million, aiming to strengthen capital and support development of its off-the-shelf cancer therapy.